(PharmaNewsWire.Com, July 09, 2017 ) Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology) The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 13, 67, 68, 1, 3, 130, 23 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 7, 10, 1, 21 and 5 molecules, respectively.
Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease) (Oncology) . - The pipeline guide reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Multiple Myeloma (Kahler Disease) (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Multiple Myeloma (Kahler Disease) (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology) . - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles 4SC AG AB Science SA AbbVie Inc Acceleron Pharma Inc Actinium Pharmaceuticals Inc Active Biotech AB Adaptimmune Therapeutics Plc Aduro BioTech Inc Aeglea BioTherapeutics Inc Affimed GmbH AIMM Therapeutics BV Alissa Pharma Altor BioScience Corp Amgen Inc Anthera Pharmaceuticals Inc APIM Therapeutics AS Arno Therapeutics Inc Array BioPharma Inc Arvinas Inc Asana BioSciences LLC Aslan Pharmaceuticals Pte Ltd Astellas Pharma Inc Astex Pharmaceuticals Inc AstraZeneca Plc Atara Biotherapeutics Inc Aurigene Discovery Technologies Ltd Bayer AG Bellicum Pharmaceuticals Inc BeyondSpring Pharmaceuticals Inc Biotest AG bluebird bio Inc Boehringer Ingelheim GmbH Boston Biomedical Inc Bristol-Myers Squibb Company Calithera Biosciences Inc CanBas Co Ltd Celgene Corp Cell Source Inc Cellectar Biosciences Inc Cellectis SA Cellerant Therapeutics Inc Celleron Therapeutics Ltd CellProtect Nordic Pharmaceuticals AB Celyad SA Chong Kun Dang Pharmaceutical Corp Chugai Pharmaceutical Co Ltd Cleave Biosciences Inc Curis Inc Cyclacel Pharmaceuticals Inc Daiichi Sankyo Company Ltd DC Prime BV Eli Lilly and Company Enceladus Pharmaceuticals BV eTheRNA Immunotherapies NV Exelixis Inc F. Hoffmann-La Roche Ltd Five Prime Therapeutics Inc Galileo Research srl Gamida Cell Ltd Genenta Science srl GlaxoSmithKline Plc Glenmark Pharmaceuticals Ltd Gliknik Inc GlycoMimetics Inc GP Pharm SA Heidelberg Pharma GmbH
List of Tables Number of Products under Development for Multiple Myeloma (Kahler Disease) , H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..5) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..6) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..7) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..8) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..9) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..10) , H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 Products under Development by Companies, H1 2017 (Contd..5) , H1 2017 Products under Development by Companies, H1 2017 (Contd..6) , H1 2017 Products under Development by Companies, H1 2017 (Contd..7) , H1 2017 Products under Development by Companies, H1 2017 (Contd..8) , H1 2017 Products under Development by Companies, H1 2017 (Contd..9) , H1 2017 Products under Development by Companies, H1 2017 (Contd..10) , H1 2017 Products under Development by Companies, H1 2017 (Contd..11) , H1 2017 Products under Development by Companies, H1 2017 (Contd..12) , H1 2017 Products under Development by Companies, H1 2017 (Contd..13) , H1 2017 Products under Development by Companies, H1 2017 (Contd..14) , H1 2017 Products under Development by Companies, H1 2017 (Contd..15) , H1 2017 Products under Development by Companies, H1 2017 (Contd..16) , H1 2017 Products under Development by Companies, H1 2017 (Contd..17) , H1 2017 Products under Development by Companies, H1 2017 (Contd..18) , H1 2017 Products under Development by Companies, H1 2017 (Contd..19) , H1 2017 Products under Development by Companies, H1 2017 (Contd..20) , H1 2017 Products under Development by Companies, H1 2017 (Contd..21) , H1 2017 Products under Development by Universities/Institutes, H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..2) , H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..4) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..5) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..6) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..7) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..8) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..9) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8) , H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by 4SC AG, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by AB Science SA, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by AbbVie Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Acceleron Pharma Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Actinium Pharmaceuticals Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Active Biotech AB, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Adaptimmune Therapeutics Plc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Aduro BioTech Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Aeglea BioTherapeutics Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Affimed GmbH, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by AIMM Therapeutics BV, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Alissa Pharma, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Altor BioScience Corp, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Amgen Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Anthera Pharmaceuticals Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by APIM Therapeutics AS, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Arno Therapeutics Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Array BioPharma Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Arvinas Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Asana BioSciences LLC, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Astellas Pharma Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Astex Pharmaceuticals Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by AstraZeneca Plc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Atara Biotherapeutics Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Bayer AG, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Biotest AG, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by bluebird bio Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Boehringer Ingelheim GmbH, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Boston Biomedical Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Bristol-Myers Squibb Company, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Calithera Biosciences Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by CanBas Co Ltd, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Celgene Corp, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Cell Source Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Cellectar Biosciences Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Cellectis SA, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Cellerant Therapeutics Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Celleron Therapeutics Ltd, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by CellProtect Nordic Pharmaceuticals AB, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Celyad SA, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Cleave Biosciences Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Curis Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by DC Prime BV, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Eli Lilly and Company, H1 2017 Multiple Myeloma (Kahler Disease) - Pipeline by Enceladus Pharmaceuticals BV, H1 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
